DINESH

Venus Remedies

Industry: Pharma B2C
Latest CMP 1,782
Today's Change ▲ 3.05%
52-Week High / Low 1,935 | 429
Price Date: 14-Aug-2026
Recommendation Buy
Target Price 2,312
Expected Upside 13.9%
Forecast Horizon 2 Years
Historical CAGR 7.1%
1,000 Invested 17-Aug-2006
Today's Value 3,976
Investment Period 20 Years

Stock Snapshot

Post Results Return
-9.6%
Mild Negative Re-rating
1-Year Target Price
2,405
2-Year Target Price
2,312
52-Week High / Low
1,935 / 429
20-Day Return
+5.9%
Market Cap (Cr.)
2,388
Current PE
21.9
P/BV Ratio
3.6
Dividend Yield
Industry PE
39.0

Price Performance

Basis of our Recommendation

Venus Remedies' outlook is shaped by stable revenue growth and consistent profit margins, reflecting management's commitment to maintaining operational efficiency amidst a competitive landscape. Recent earnings calls indicate a focus on expanding their portfolio in biosimilars and innovative therapies, which are critical for enhancing market share and long-term growth. This strategic direction aligns with Vista's forecast of stable revenue growth, as the company capitalizes on favorable industry dynamics, including improving pricing power and a robust pipeline of new products. The Indian pharmaceutical sector is experiencing expansion, supported by currency depreciation benefits and increasing export opportunities, which further bolsters Venus Remedies' revenue potential. However, the company must navigate margin pressures stemming from rising input costs, particularly in the US market. Over the next 12-24 months, key opportunities lie in leveraging their R&D capabilities to introduce higher-margin products, while watchpoints include the potential impact of fluctuating crude oil prices and competitive pressures from larger players in the market. Overall, Vista's investment outlook remains cautiously optimistic, with a target price reflecting a modest expected upside, underpinned by a stable financial structure and fair valuation

👍 Why We Like This Stock

Things To Watch Out For

Key Parameters

Balance Sheet Strength
Stable Financial Structure
Market Share
Stable
Industry Outlook
Improving
Analyst View
Not Available
Dividend History
Irregular
FII Holdings
Stable

Financial Snapshot

Actuals Forecast
FY24 FY25 FY26 FY27 FY28
Revenue (Cr.) 596 640 770 885 930
Profit Before Tax (Cr.) 44 60 134 191 191
PBT Margin 7.5% 9.4% 1740.3% 21.6% 20.5%
Net Profit (Cr.) 32 44 101 144 144
Earnings Per Share 24.2 33.2 75.4 107.6 107.6

Analyst Recommendations

No analyst recommendations available.

Consensus Recommendation ► None
Consensus Target
Coverage 0 Analysts
Analysts' Viewpoint

Company Overview

Show Company Profile

Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, and solvent products, as well as herbal medicine. The company was incorporated in 1989 and is headquartered in Panchkula, India.